Advertisement

Topics

Celgene to Present New Data from Clinical Trials on Oral OTEZLA® (apremilast) at American Academy of Dermatology Congress

07:00 EST 3 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
UNVEIL evaluated the efficacy and safety of oral OTEZLA at 16 weeks in patients with moderate plaque psoriasis who were naïve to systemic and biologic therapy Celgene Corporation (NASDAQ:CELG) today announced that findings ...

Other Sources for this Article

Celgene Corporation
Investors:
Patrick E. Flanigan III, 908-673-9969
Corporate Vice President, Investor Relations
or
Media:
Catherine Cantone, 908-897-4256
Senior Director, Corporate Communications

NEXT ARTICLE

More From BioPortfolio on "Celgene to Present New Data from Clinical Trials on Oral OTEZLA® (apremilast) at American Academy of Dermatology Congress"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...